SCHEMBL5214838

SCHEMBL5214838

COP(=O)(Cc1ccc(NC(=O)CCc2oc(-c3ccccc3)nc2-c2ccc(Cl)cc2)cc1)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.49
MAPT P10636 5/20 0.49
NPSR1 Q6W5P4 2/20 0.49
SMO Q99835 2/20 0.46
ALDH1A1 P00352 4/20 0.44
HPGD P15428 4/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
HSD17B10 Q99714 3/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
CACNA1B Q00975 1/20 0.44
APBA1 Q02410 1/20 0.44
CETP P11597 5/20 0.43
POLB P06746 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
STAT3 P40763 1/20 0.42
KDR P35968 2/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5209675 0.95 KDM4E (0.48) KDM4EMAPTNPSR1SMOALDH1A1
SCHEMBL5214884 0.91 SMO (0.44) KDM4EMAPTNPSR1SMOALDH1A1
SCHEMBL5211339 0.87 MAPT (0.47) KDM4EMAPTNPSR1SMOALDH1A1
SCHEMBL5207445 0.86 MEN1 (0.49) KDM4EMAPTALDH1A1HPGDMEN1
SCHEMBL5213161 0.85 MAPT (0.49) KDM4EMAPTNPSR1SMOALDH1A1
SCHEMBL5208465 0.85 MAPT (0.49) KDM4EMAPTNPSR1SMOALDH1A1
SCHEMBL5207604 0.85 TP53 (0.47) KDM4EMAPTNPSR1ALDH1A1MEN1
SCHEMBL5213177 0.84 MAPT (0.40) KDM4EMAPTNPSR1MEN1KMT2A
SCHEMBL5211438 0.83 MAPT (0.50) KDM4EMAPTNPSR1SMOALDH1A1
SCHEMBL5209787 0.83 LTA4H (0.50) KDM4EMAPTNPSR1SMOALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US claimed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP claimed
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 KDM4E 2428/4885MAPT 3958/4885NPSR1 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.